SNSP 113

Drug Profile

SNSP 113

Alternative Names: SYGN-113

Latest Information Update: 14 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Synedgen
  • Developer Synedgen; Synspira
  • Class Glycosaminoglycans; Polymers; Polysaccharides; Small molecules
  • Mechanism of Action Cystic fibrosis transmembrane conductance regulator stimulants; Glycoprotein modulators; Polysaccharide modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cystic fibrosis

Most Recent Events

  • 12 Jul 2017 Pharmacodynamics data from a preclinical study in Cystic fibrosis released by Synspira
  • 29 Jun 2017 Synspira plans a phase I trial for Cystic fibrosis in USA
  • 29 Jun 2017 SNSP 113 exclusively licensed to Synspira
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top